Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Acute Biphenotypic Leukemia (ABL): early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Acute Biphenotypic Leukemia (ABL): 1 US clinical trial tracked, none currently recruiting.

Acute Biphenotypic Leukemia (ABL) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Center for International Blood and Marrow Transplant Research, running 1 of these trials.

Enrollment posture brief

Registry condition acute-biphenotypic-leukemia-abl

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Acute Biphenotypic Leuke (th…0%
Open-enrollment share among volume-matched conditions near Acute Biphenotypic Leukemia (ABL)

Acute Biphenotypic Leukemia (ABL) has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Acute Biphenotypic Leukemia (ABL) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Acute Biphenotypic Leukemia (ABL) is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Acute Biphenotypic Leukemia (ABL) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Infusion of non-T-cell depleted bone marrow on Day 0 Procedure
1 trials
Total Body Irradiation (TBI) 200cGy on Day -1 Radiation
1 trials
Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5 Drug
1 trials
Busulfan Drug
1 trials
Fludarabine Drug
1 trials

US sites by state

Facility locations filed on Acute Biphenotypic Leukemia (ABL) trials. A trial with sites in several states counts in each.

Wisconsin 1 trials
Virginia 1 trials
Ohio 1 trials
New York 1 trials
North Carolina 1 trials
Michigan 1 trials
Maryland 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Acute Biphenotypic Leukemia (ABL) page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Biphenotypic Leukemia (ABL) condition card totals 1 registered trials; most-linked intervention Infusion of non-T-cell depleted bone marrow on Day 0; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.